The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
STEP: Semaglutide s.c. once-weekly for weight management
Recently recognised by the European Commission as a chronic relapsing disease1, obesity affects an increasingly substantial group of people, who faces complications such as diabetes, cardiovascular disease, arthritis or even cancer2. Achieving weight loss is notoriously hard - for many, maintaining a successful weight reduction is even more difficult. Pharmacotherapies for weight management may help people achieve and maintain their optimal body weight.